News Article
Quick-Release Bromocriptine Reduces HbA1c in Type 2 Diabetes Patients Taking Other Oral Agents
ROME (EGMN) - An investigational quick-release formulation of bromocriptine significantly reduced hemoglobin A
Cycloset, developed by VeroScience LLC, is a novel quick-release formulation of the dopamine-2 receptor agonist bromocriptine. Carefully timed morning administration is crucial to its function, because circadian neuroendocrine rhythms in the hypothalamus regulate the peripheral metabolism. In diabetes patients, morning administration of the centrally acting agent reestablishes the daily peak of dopaminergic activity, resulting in improved hepatic and muscle insulin resistance, primarily following a meal.
Consequently, Cycloset's effect on glycemic control may be additive to a variety of peripherally acting oral hypoglycemic agents (OHAs), Dr. Anthony H. Cincotta said at the annual meeting of the European Association for the Study of Diabetes.
A total of 559 patients with hemoglobin A
A total of 376 patients received Cycloset and 183 received placebo. Prespecified subgroups included those taking a sulfonylurea with or without another OHA, those taking metformin with or without another OHA, and those taking both metformin and a sulfonylurea. Additional post hoc analyses included patients on thiazolidinediones with or without an OHA, and those taking metformin plus glyburide therapy. Dosages of the concomitant OHAs were adjusted if necessary.
At 24 weeks, significant reductions in HbA
Reductions in HbA
In a larger safety study of 3,070 patients, including the 559 analyzed here, placebo-subtracted discontinuations due to adverse events were 7.7% for nausea, 2.6% each for dizziness and fatigue, and 1.9% for headache. All-cause adverse events did not differ between the Cycloset and placebo groups. In a previously reported analysis of cardiovascular outcomes among the total 3,070 patients, the composite outcome of myocardial infarction, stroke, hospitalization for unstable angina, heart failure, or revascularization surgery was reduced by 42% with Cycloset, compared with placebo, Dr. Cincotta reported.
All articles have been reviewed by members of our Editorial Board or independent referees.
You need Adobe Acrobat Reader installed on your computer to read the PDF version of these articles. If you don't have Acrobat Reader, click here to download it free.
